



Ferrata Storti Foundation

A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia

Renato Bassan,¹ Monika Brüggemann,² Hoi-Shen Radcliffe,³ Elizabeth Hartfield,⁴ Georg Kreuzbauer⁵ and Sally Wetten³

¹Complex Operative Unit of Haematology, dell'Angelo Hospital and Santissimi Giovanni and Paolo Hospital, Mestre and Venice, Italy; ²Department of Medicine II, Schleswig-Holstein University Hospital, Kiel, Germany; ³Amgen Ltd, Uxbridge, UK; ⁴Oxford PharmaGenesis, Oxford, UK and ⁵Amgen (Europe) GmbH, Zug, Switzerland

Haematologica 2019
Volume 104(10):2028-2039

ABSTRACT

Minimal (or 'measurable') residual disease in acute lymphoblastic leukemia appears to be a prognostic indicator, with potential value in informing individualized treatment decisions. Complete understanding of the strength of the association between minimal residual disease and long-term outcomes is, however, lacking. A systematic literature review and meta-analysis were performed to elucidate the clinical significance of minimal residual disease with respect to relapse-free survival and overall survival in precursor B-cell acute lymphoblastic leukemia. A total of 23 articles and abstracts, most published between 2012 and 2016, were identified for inclusion in the primary meta-analysis. Typically, patients were in their first complete remission at the time of minimal residual disease assessment; in two studies, all patients were in their second, or later, complete remission. The primary analysis revealed improved relapse-free survival across all studies for patients who achieved minimal residual disease negativity (random effects hazard ratio, 2.34; 95% confidence interval, 1.91–2.86). Improved overall survival for patients who achieved minimal residual disease negativity was also observed (hazard ratio, 2.19; 95% confidence interval, 1.63–2.94). There was no observed difference in the impact of minimal residual disease status in subgroups based on disease stage, minimal residual disease sensitivity threshold level, Philadelphia chromosome status, histological phenotype, risk group, minimal residual disease testing location, minimal residual disease timing after induction, or minimal residual disease detection method. Despite heterogeneity in study design and patient populations between the contributing studies, these data provide a compelling argument for minimal residual disease as a clinical tool for assessing prognosis and guiding treatment decisions in precursor B-cell acute lymphoblastic leukemia.

Correspondence:

RENATO BASSAN
renato.bassan@aulss3.veneto.it

Received: July 2, 2018.

Accepted: March 14, 2019.

Pre-published: March 19, 2019.

doi:10.3324/haematol.2018.201053

Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/104/10/2028

©2019 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

<https://creativecommons.org/licenses/by-nc/4.0/legalcode>.

Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

<https://creativecommons.org/licenses/by-nc/4.0/legalcode>,

sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.



Introduction

Acute lymphoblastic leukemia (ALL) is a heterogeneous disease that derives from lymphoid cell populations.¹ Precursor B-cell ALL (B-ALL) is the most common immunological subtype,² and the most common genetic abnormality in B-ALL is the Philadelphia chromosome (Ph-positive ALL), found in approximately one-quarter of adult patients.³ Genetic or molecular profiling can be used to characterize disease prognosis, predict response to therapy, and inform treatment decisions.^{4,5}

The mainstay of treatment for patients with newly diagnosed B-ALL has historically involved induction chemotherapy, followed by consolidation and maintenance chemotherapies; allogeneic hematopoietic stem cell transplantation (HSCT) is recommended following consolidation in selected high-risk groups.⁶ However,

for patients with Ph-positive disease in particular, outcomes with standard combination chemotherapy are poor.⁵ The tyrosine kinase inhibitors imatinib, dasatinib, nilotinib, and ponatinib have shown efficacy in patients with Ph-positive disease, and there are some preliminary suggestions that they may also be efficacious in selected subsets of Ph-negative ALL.^{6–8} Moreover, several targeted therapies have been developed for patients with B-ALL, such as the antibody-based therapies rituximab, inotuzumab ozogamicin and blinatumomab, these latter demonstrating greater effectiveness than salvage chemotherapy in the very high-risk setting of relapsed/refractory ALL, including both Ph-positive and Ph-negative patients.^{9–11}

The introduction of targeted therapies, alongside advances in diagnostic procedures, have improved outcomes for patients with B-ALL.^{12,13} However, despite a substantial proportion (74% to 91%) of patients achieving complete remission (CR), one-third or more will eventually relapse because of the presence of submicroscopic levels of leukemic cells in the bone marrow.^{14–18} The presence of these remaining cancer cells is known as minimal residual disease (MRD; alternatively termed ‘measurable residual disease’).

MRD is increasingly being used in clinical practice as an independent prognostic marker for the duration of CR and long-term outcomes in patients with ALL, and for informing treatment decisions.^{19–22} The European Society for Medical Oncology (ESMO) and National Comprehensive Cancer Network clinical practice guidelines for adult patients with ALL recommend the quantification of MRD whenever possible,^{6,23,24} but it is not yet clear whether MRD status alone is sufficient to predict prognosis, or whether it should be combined with other parameters, such as patient-related (e.g., age) or disease-related (e.g., cytogenetics) risk factors. In drug development, MRD response has been considered as an early marker of efficacy in clinical studies, with potential use as a surrogate endpoint in registration studies for accelerated drug approval.^{25,26} A full understanding of the prognostic significance of MRD is needed to guide its use across this broad range of settings.

A large number of studies have shown that achievement of MRD-negative status correlates positively with CR duration, reduced risk of relapse, and HSCT success.^{22,27} The use of MRD testing is individualized within a given study protocol, and hence there is wide variation in the test method used, the timing and sensitivity of MRD assessment, the characteristics of the patients, and the treatments used before and after MRD was assessed. We conducted a systematic review to capture the evidence supporting the clinical significance of MRD on clinical outcomes and used this evidence to inform a meta-analysis with the aim of quantifying the impact of MRD status on relapse-free survival (RFS) and overall survival (OS). A recent meta-analysis suggested that event-free survival and OS were almost always better in patients with ALL who were MRD negative than in those who were MRD positive.²⁸ This meta-analysis included studies in children and adults, and in B-cell and T-cell phenotypes. Our meta-analysis focused on adult patients with B-ALL and includes 23 studies, 18 of which were not in the previous meta-analysis, which enabled us to explore the impact of MRD status within clinically important subgroups in this population.

Methods

Systematic literature review

Evidence base

We systematically reviewed published studies according to a prespecified protocol, using a process compliant with the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.²⁹ PubMed and Embase databases were searched (*Online Supplementary Table S1*) for studies in humans published in English between 1 January, 1995 and 1 March, 2016. Additional searches were conducted for congress proceedings [American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), European Hematology Association (EHA), and ESMO] published between 2012 and 2016.

Screening and data extraction

Titles or abstracts identified from the initial searches were evaluated against the prespecified inclusion criteria (*Online Supplementary Methods*). The full texts were obtained for all studies deemed eligible, and for studies whose eligibility was unclear during the title/abstract screening. The full texts were independently screened by two reviewers to confirm which studies should be included. Any discrepancies were resolved by a third reviewer. Data extraction is described in the *Online Supplementary Methods*.

Meta-analysis

Evidence base

Studies identified from the systematic literature review were excluded from the meta-analysis if RFS was not reported separately for patients who were MRD-negative and MRD-positive in status, or if insufficient data were reported to calculate a hazard ratio according to the methods outlined in Tierney *et al.*³⁰ For studies that included patients with B-ALL and T-cell ALL (T-ALL), hazard ratios were calculated only for the patients with B-ALL, if it was possible to do so.

Outcomes

The primary outcome was RFS – alternatively termed disease-free, event-free or leukemia-free survival in some publications. In studies that provided RFS definitions, RFS was mostly measured from CR until relapse or death. Other studies that provided a definition measured RFS from HSCT^{31–33} or from the start of treatment.^{34–36} For the purposes of the meta-analysis, we used the measure of RFS as provided in each study publication. The primary analysis set was based on studies that reported RFS according to MRD status. The secondary outcome was OS, determined from those studies in the primary analysis set that also reported OS according to MRD status.

Statistical analysis

The analysis of hazard ratios used unadjusted measures of treatment effect, where available. Meta-analysis was performed using the random effects model.^{37,38} Heterogeneity between studies was assessed statistically using the I^2 and Cochran Q tests.^{39,40} Meta-regression was performed to investigate the relationships between covariates (Ph status, median follow-up time, MRD cut-off sensitivity threshold, post-MRD treatment, disease stage, sex and age) and study-level hazard ratios.³⁸

Results

Search results

The systematic literature search identified 1,899 records (1,252 full papers and 647 congress abstracts) for

title and abstract screening. An additional four full papers were included that were not identified during the systematic literature searches, giving a total of 1,903 records (Figure 1). Following screening of the title and abstract of each record, 278 records were included in the full text screen. Finally, 33 full papers and 21 congress abstracts were covered in the systematic review; these included 8,820 patients with B-ALL, 5,979 of whom had available MRD data. The study and patients' characteristics, together with clinical outcomes, are summarized in *Online Supplementary Tables S2–S7*. In total, 32 records

(23 full texts and 9 congress abstracts) were eligible for the meta-analysis; of these, 23 records were included in the primary analysis set; the remaining papers were excluded because either the study populations overlapped with another, more recent, publication, and there were no unique data for inclusion in the meta-analysis, or inconsistencies in data reporting meant that it was not possible to calculate hazard ratios. A list of studies identified in the systematic review but not included in the meta-analysis, with reasons, is provided in *Online Supplementary Table S8*.




Figure 1. PRISMA flow diagram. ^aIncludes four full text articles that were not identified during the systematic literature searches. ^bProtocol amendment. Includes disease-free survival, leukemia-free survival and duration of complete response or progression-free survival. ALL: acute lymphoblastic leukemia; B cell ALL/B-ALL: B-cell acute lymphoblastic leukemia; HR: hazard ratio; MRD: minimal residual disease; MRD-: minimal residual disease-negative status; MRD+: minimal residual disease-positive status; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RFS: relapse-free survival; T cell ALL/T-ALL: T-cell acute lymphoblastic leukemia.

Characteristics of studies and patients in the meta-analysis

Disease stage and treatment

Key characteristics of the studies included in the meta-analysis (Table 1) were considered in order to provide con-

text when analyzing clinical outcomes according to MRD status.^{20,31-36,41-56} Most studies assessing MRD status in adults with B-ALL were published from 2011 onwards, with the exception of a prospective study in Germany³⁵ and a Polish study.⁴⁷ Studies were mainly conducted in

Table 1. Characteristics of studies included in the meta-analysis.

First author	Year	Total number of patients (with MRD data)	Ph status	MRD method	MRD level	MRD test location	ALL phenotype	MRD timing	Disease stage at MRD	Pre-MRD tx	Post-MRD tx	Risk group
Included in primary analysis												
Lussana ⁵⁶	2016	106 (73)	Pos	PCR	10 ⁻⁵	NA	B-cell	Pre-HSCT	CR1	Targeted	HSCT	NA
Gökbuget ⁴¹	2015	116 (112)	Neg	PCR	10 ⁻⁴	Central	B-cell	≤ 3 months from induction	CR1 ^a	Targeted	Mix	NA
Chiaretti ⁴²	2015	63 (60)	Pos	PCR	NA	NA	B-cell	≤ 3 months from induction	CR1	Targeted	Mix	NA
Jabbour ⁴³	2017	78 (78)	NA	Flow (6 color)	10 ⁻⁴	Local	B-cell	≤ 3 months from induction	CR2 or later	Targeted	Mix	NA
Nishiwaki ³⁴	2016	432 (432)	Pos	PCR	10 ⁻⁵	Local	B-cell	Pre-HSCT	CR1	Targeted	HSCT	NA
Ravandi ⁴⁴	2016	340 (260)	Mix	Flow (6 color)	10 ⁻⁴	Local	B-cell	≤ 3 months from induction	CR1	Targeted	Mix	NA
Bassan ⁴⁹	2014	159 (106)	Neg	PCR	10 ⁻⁴	NA	Mix (79% B-cell)	≥ 3 months from induction	CR1	Chemo	Mix	Mix
Beldjord ⁴⁶	2014	860 (423)	Neg	PCR	10 ⁻⁴	Central	B-cell	≤ 3 months from induction	CR1	Chemo	Mix	Mix
Gökbuget ²⁰	2012	1648 (580)	Neg	PCR	10 ⁻⁴	Central	Mix (66% B-cell)	≤ 3 months from induction	CR1	Chemo	Mix	Mix
Holowiecki ⁴⁷	2008	131 (116)	Neg	Flow (3 color)	10 ⁻³	Central	Mix (75% B-cell)	≤ 3 months from induction	CR1	Chemo	Mix	Mix
Patel ³⁸	2010	161 (161)	Neg	PCR	10 ⁻⁴	NA	B-cell	≤ 3 months from induction	CR1	Chemo	Mix	Mix
Bassan ⁴⁵	2014	304 (141, [98 included in the analysis])	Neg	PCR	10 ⁻⁴	NA	Mix (76% B-cell)	> 3 months from induction	CR1	Chemo	Mix	Mix
Gökbuget ³⁶	2014	189 (73)	Neg	PCR	10 ⁻⁴	Central	B-cell	≤ 3 months from induction	CR2 or later	Targeted	Mix	Mix
Bachanova ³¹	2014	197 (185)	Pos	PCR	NA	Local	B-cell	Pre-HSCT	CR1	Targeted	HSCT	NA
Giebel ³²	2010	123 (123)	Neg	Mix	10 ⁻³	Local	B-cell	Pre-HSCT	CR1	Chemo	HSCT	High
Tucunduva ³³	2014	98 (98)	Pos	Mix	Mix	Local	B-cell	Pre-HSCT	CR1 ^b	Targeted	HSCT	NA
Wassmann ³⁵	2005	27 (27)	Pos	PCR	NA	Central	B-cell	Post-HSCT	CR1 ^c	HSCT	Targeted	NA
Weng ⁵⁰	2013	125 (106)	Mix	Flow (6 color)	10 ⁻⁴	Local	B-cell	≤ 3 months from induction	CR1	Chemo	Mix	NA
Yanada ⁵¹	2008	100 (85)	Pos	PCR	10 ⁻⁵	Central	B-cell	≤ 3 months from induction	CR1	Targeted	Mix	NA
Wetzler ⁵²	2014	34 (13)	Pos	PCR	NA	Central	B-cell	Post-HSCT	CR1	Targeted	NA	NA
Yoon ⁵³	2016	173 (169)	Pos	PCR	10 ⁻⁴	Central	B-cell	Pre-HSCT	CR1	Targeted	HSCT	NA
Lim ⁵⁴	2016	82 (78)	Pos	PCR	10 ⁻⁵	Central	B-cell	≤ 3 months from induction	CR1	Targeted	Mix	NA
Short ⁵⁵	2016	202 (122)	Pos	PCR	10 ⁻⁴	NA	B-cell	≤ 3 months from induction	CR1	Targeted	Targeted	NA
Included in subgroup analysis												
Ravandi ^{44,d}	2016	340 (260)	Mix	Flow	10 ⁻⁴	Local	B-cell	> 3 months from induction	CR1	Targeted	Mix	NA
Gökbuget ^{20,d}	2012	1648 (580)	Neg	PCR	10 ⁻⁴	Central	Mix (66% B-cell)	> 3 months from induction ^e	CR1	Chemo	Mix	Standard/high
Holowiecki ^{47,d}	2008	131 (116)	Neg	Flow (3 color)	10 ⁻³	Central	Mix (75% B-cell)	> 3 months from induction	CR1	Chemo	Mix	Mix
Patel ^{38,d}	2010	161 (161)	Neg	PCR	10 ⁻⁴	NA	B-cell	> 3 months from induction/pre-HSCT ^e	CR1	Chemo	HSCT/ Chemo	Standard/high

^aCR1 65%, CR2 34%, CR3 2%; ^bCR1 81%, CR2 19%; ^cCR1 78%, CR2 22%; ^dStudy included in primary analysis with additional subgroups available for inclusion in subgroup analyses.

^eMinimal residual disease was assessed at multiple time points, both ≤3 months and >3 months after induction. ALL: acute lymphoblastic leukemia; Central: central laboratory; CR1: first complete remission; CR2: second complete remission; CR3: third complete remission; Chemo: chemotherapy; Flow: flow cytometry; HSCT: hematopoietic stem-cell transplantation; Local: local laboratory; Mix: mixed; MRD: minimum residual disease; NA: not available; Neg: negative; PCR: polymerase chain reaction; Ph: Philadelphia chromosome; Pos: positive; R/R: relapsed and/or refractory; Targeted: targeted agent (e.g., tyrosine kinase inhibitor, blinatumomab, inotuzumab); tx: treatment.

Europe or East Asia, and almost all studies prospectively assessed MRD; only two studies included patients exclusively in second CR (CR2) or later, and the rest were in patients in first CR (CR1) at the time of MRD assessment (of these, three studies included a minority of patients in CR2 or later in combination with patients in CR1, and these were categorized as CR1 for the purposes of the meta-analysis). Approximately half were in Ph-positive patients ($n=11$), and these patients had typically received chemotherapy plus a tyrosine kinase inhibitor before their MRD assessment (*Online Supplementary Table S2*). Most patients with Ph-negative ALL received chemotherapy, with or without targeted agents. As mentioned, there were only two studies in which all patients were in CR2 or later, and these patients had received treatment with blinatumomab or inotuzumab ozogamicin, with or without chemotherapy, before MRD was assessed.^{36,43} Two studies, in Ph-positive patients, examined the impact of MRD status following transplantation.^{35,52}

Treatment received after MRD assessment varied across, and within, the studies; in most studies ($n=14$), pooled survival outcomes were reported for the mix of post-MRD treatments (targeted therapy, chemotherapy and HSCT) (Table 1). Six studies reported outcomes separately for patients who received an HSCT after their MRD assessment; a further two studies reported outcomes separately for post-MRD treatment with a targeted agent.

Minimal residual disease assessment methodology and timing

MRD was most commonly assessed at a central laboratory ($n=10$); other studies used a local reference laboratory ($n=7$) or did not specify whether centralized assessment was performed ($n=6$). A range of methodologies were used to assess MRD, although most ($n=17$) were polymerase chain reaction (PCR) based (Table 1). All but one of the studies of patients with Ph-negative ALL used PCR-based methodologies; three specified that they looked for immunoglobulin or T-cell receptor gene rearrangements (*Online Supplementary Tables S2 and S3*). The remaining study used multiparameter flow cytometry (*Online Supplementary Table S2*). For patients who had Ph-positive ALL, all studies ($n=11$) used BCR-ABL as a marker of MRD; most ($n=9$) used real-time quantitative PCR, one study used molecular testing and one study used fluorescent *in-situ* hybridization. The most commonly used sensitivity limit was 1 in 10^4 cells for all methodologies, and sensitivities of 1 in 10^5 cells were only reported for PCR-based detection in studies of patients with Ph-positive status (Table 1). The three studies that included patients with mixed Ph status or did not report Ph status all used multiparameter flow cytometry (22%) (*Online Supplementary Tables S2 and S3*). The number of colors used ranged from three to eight, and no trends in the number of colors used were observed over time in the studies.

MRD measurements were generally taken within 3 months of induction treatment ($n=14$) (*Online Supplementary Tables S2 and S3*).

Clinical outcomes according to minimal residual disease status

Relapse-free survival

Figure 2 shows the meta-analysis results for the 23 studies included in the primary analysis. The overall results show improved RFS for patients who achieved MRD negativity [random effects hazard ratio (HR)=2.34; 95% con-

fidence interval (CI): 1.91–2.86], and the effect was seen consistently across all studies.

The I^2 value was 59%, indicating moderate-to-high heterogeneity between the studies in the primary analysis. This effect was anticipated given the known variations between studies in the design, patients' characteristics and treatments received. For this reason, a predefined set of subgroups was examined to explore whether MRD negativity had a consistent effect in important subgroups of patients.

All subgroups showed an improved RFS in patients who achieved MRD negativity; no significant differential subgroup effects were observed (Figure 3). Although it should be noted that for some subgroups there were very few studies available, which contributed to overlapping confidence intervals, some trends were seen. The prognostic value of MRD appeared stronger in patients who received chemotherapy than in those who received targeted therapy before MRD assessment (HR=2.98; 95% CI: 2.12–4.20 and HR=0.90; 95% CI: 1.53–2.36, respectively), but the confidence intervals overlap. The subgroup that received HSCT before MRD assessment has a hazard ratio of 5.19 (95% CI: 1.95–13.8), but it should be noted that this is based on one study, and the confidence intervals are very wide. The prognostic value of MRD also seemed to be stronger in patients who received chemotherapy after their MRD assessment (HR=6.52; 95% CI: 2.43–17.5) than in those who received HSCT after MRD assessment (HR=1.73; 95% CI: 1.27–2.37), but again it should be noted that the data for chemotherapy after MRD assessment are from only one study.

The subgroup analysis was repeated separately according to Ph status and timing of MRD assessment (*Online Supplementary Figures S1 and S2*). There was no difference in RFS improvement for patients who achieved MRD negativity between studies in the Ph-positive (HR=2.04; 95% CI: 1.53–2.73) and Ph-negative (HR=2.46; 95% CI: 2.02–2.98) groups. Hazard ratios in all subgroups favored MRD negativity, regardless of Ph status, with no apparent difference between Ph-positive and Ph-negative cases in any subgroup (*Online Supplementary Figure S1*). Similarly, there was no difference in RFS improvement for patients who achieved MRD negativity at early timepoints (within 3 months from induction: HR=2.60; 95% CI: 2.05–3.31) and later timepoints (more than 3 months from induction: HR=2.23; 95% CI: 1.67–2.97). Hazard ratios were more favorable in most subgroups at the early MRD timepoint compared with the later MRD timepoint group, but the subgroup confidence intervals overlapped between the early and later MRD timepoints (*Online Supplementary Figure S2*).

Overall survival

The meta-analysis results for the 14 studies included in the secondary (OS) analysis are summarized in Figure 4. The overall results show improved OS for patients who achieved MRD negativity (HR=2.19; 95% CI: 1.63–2.94). Individually, the results were consistently in favor of MRD negativity across all the studies with the exception of that by Bachanova *et al.*,³¹ who reported a hazard ratio of 0.94, but with a confidence interval that crossed the null value (95% CI: 0.65–1.35). Four other studies also had confidence intervals that crossed the null value.^{36,43,44,56}

The I^2 value was greater for the OS analysis (67%) than for the RFS analysis (59%), again confirming the extent of

the heterogeneity in the studies in terms of design, populations and treatment protocols. Reassuringly, a predefined analysis of key subgroups of interest showed a consistent improvement in OS in patients who achieved MRD negativity (Figure 5). As for RFS, no significant differential subgroup effects were seen. The prognostic value of MRD appeared to be greater in patients who received HSCT before MRD assessment (HR=8.02; 95% CI: 2.32–27.7) than those assessed after chemotherapy (HR=3.01; 95% CI: 2.08–4.37) or targeted therapy only (HR=1.65; 95% CI: 1.24–2.20). The prognostic value of MRD was less notable in patients who received HSCT treatment after MRD assessment (HR=1.24; 95% CI: 0.86–1.78) than those who received alternative interventions (HR=2.50; 95% CI: 1.88–3.33). As for RFS, the number of studies in some subgroups was small, and many of the confidence intervals overlapped.

Meta-regression

Meta-regression was explored to further investigate the heterogeneity between studies. The analysis was limited

by the small number of studies that provided information for certain covariates (i.e. those used to define the subgroups), and for this reason we focused on RFS for which more studies were available. Heterogeneity remained even after adjustment for almost all covariates, as reflected by a significant within-group Q-statistic (Qw) (*Online Supplementary Table S9*). The exception was risk group; however, interpretation of the relevance of this covariate is limited by its inclusion in only three studies.

Of note, the Tierney method³⁰ used to calculate the hazard ratio for each study had no significant effect on the treatment difference.

Discussion

This systematic review and meta-analysis found that in adults with B-ALL, achieving MRD negativity was consistently associated with better survival outcomes than those of patients with MRD-positive status. In addition, the benefit of achieving MRD negativity was evident in all the




Figure 2. Forest plot of relapse-free survival hazard ratios for all studies included in the primary analysis. CI: confidence interval; HR: hazard ratio; MRD: minimal residual disease; MRD neg: minimal residual disease-negative status; MRD pos: minimal residual disease-positive status.

subgroups that we examined, highlighting its relevance for assessing prognosis and measuring treatment efficacy. There were some preliminary indications that MRD status may have a greater effect on outcomes in certain patient subgroups than in others. These data should be interpreted with caution, since no significant differential subgroup

effects were seen, and most of the confidence intervals overlapped.

Our data build upon evidence from a recent meta-analysis of patients with B-ALL or T-ALL by Berry *et al.* that showed hazard ratios for event-free survival and OS almost uniformly favor MRD negativity, and that this




Figure 3. Forest plot of relapse-free survival hazard ratios by subgroup (random effects model). B cell ALL/B-ALL: B-cell acute lymphoblastic leukemia; CI: confidence interval; CR1: first complete remission; CR2: second complete remission; Chemo: chemotherapy; Flow: flow cytometry; HR: hazard ratio; HSCT: hematopoietic stem-cell transplantation; MRD: minimal residual disease; MRD neg: minimal residual disease-negative status; MRD pos: minimal residual disease-positive status; N: number of studies; PCR: polymerase chain reaction; Ph: Philadelphia chromosome; SCT: stem-cell transplantation; targeted: targeted agent (e.g., tyrosine kinase inhibitor, blinatumomab, inotuzumab); tx: treatment.

effect is retained within each of the subgroups.²⁸ The hazard ratio effect size appears slightly larger than in our meta-analysis, which could reflect differences in the studies included or the different analysis approach that was used (with a Bayesian rather than a random effects model). There was only partial overlap in studies between the two meta-analyses, with five studies included in both,^{20,33,46-48} meaning that our study adds 18 studies and 2,245 patients to the combined evidence base. Only one of the adult studies in the analysis by Berry *et al.* was identified as concerning B-ALL,⁴⁸ but our efforts to extract data from the B-ALL populations wherever possible allowed us to conduct subgroup analyses specific for this phenotype with 19 studies of RFS and 12 studies of OS. Similarly, we calculated outcomes according to Ph status for a larger number of studies (20 vs. 8 in Berry *et al.*), enabling a more robust subgroup analysis and allowing further subgroup analyses to be conducted within each cytogenetic category. The lack of overlap between the two meta-analyses was likely due to differences in eligibility criteria: our study allowed for a larger range of methods to calculate hazard ratios (as described in Tierney *et al.*⁵⁰), only excluding studies with small patient numbers if MRD was examined retrospectively, and included congress abstracts. Our study focused on a narrower population than that of Berry *et al.*, but a high degree of heterogeneity remained; this highlights the limitations of conducting meta-analyses according to MRD status and should encourage future research using pooled analysis of patient-level data.

In general, MRD evaluations are conducted in two different scenarios. The first is in patients who achieve mor-

phological remission after receiving induction therapy, at the time of remission evaluation or shortly after, to evaluate the quality of the response. The second scenario is to use MRD monitoring as a predictor for pending relapse. We examined subgroups according to the timing of MRD assessment, either before or after 3 months from starting induction, or before or after HSCT. MRD assessments up to 3 months from induction were generally taken during or at the end of induction treatment – i.e. before consolidation or intensification therapy – and this subgroup therefore falls into the first scenario. In our analysis, there was little difference in the relative effect of MRD assessed at 3 months or later, and four studies that evaluated outcomes from multiple MRD timepoints showed a beneficial effect of MRD negativity at both earlier and later timepoints. Furthermore, subgroup analysis of RFS according to the timing of MRD assessment showed that there was no difference in RFS improvement for patients who achieved MRD negativity at early timepoints compared to those who achieved it at later timepoints. Measurement of MRD after HSCT may also fall into the second scenario, and the apparently large impact of MRD on RFS and OS in the post-HSCT subgroup may reflect the strong predictive ability of MRD to detect relapse in this setting.

Nevertheless, the timing of MRD measurement is an important consideration if the technique is to be used to support treatment decisions, and evidence exists to support early MRD testing. For example, in a study conducted in the USA that enrolled patients with Ph-negative B-ALL or T-ALL, MRD levels as early as 28 days following the initiation of induction therapy were used to predict out-




Figure 4. Forest plot of overall survival hazard ratios for all studies included in the primary analysis. CI: confidence interval; HR: hazard ratio; MRD: minimal residual disease; MRD neg: minimal residual disease-negative status; MRD pos: minimal residual disease-positive status.

comes.⁵⁷ In another study assessing patients with Ph-negative B-ALL or T-ALL, an early MRD response (day 11) was associated with the best prognosis.⁵⁸ In addition, in an analysis of patients with Ph-negative ALL from France, Belgium and Switzerland, lack of MRD response 6 weeks after induction initiation could identify patients who would benefit most from HSCT.⁵⁹ This highlights the

importance of early testing if MRD status is to be used to influence treatment decisions.

Information from MRD testing could help to target highly effective immunotherapies, as well as therapies that are less well tolerated, such as HSCT, to those at high risk of relapse. In a study of Ph-negative patients from the GRAALL-2003 or -2005 trials, transplant was found to




Figure 5. Forest plot of overall survival hazard ratios by subgroup (random effects model). B cell ALL/B-ALL: B-cell acute lymphoblastic leukemia; CI: confidence interval; CR1: first complete remission; CR2: second complete remission; chemo: chemotherapy; Flow: flow cytometry; HR: hazard ratio; HSCT: hematopoietic stem-cell transplantation; MRD: minimal residual disease; MRD neg: minimal residual disease-negative status; MRD pos: minimal residual disease-positive status; N: number of studies; PCR: polymerase chain reaction; Ph: Philadelphia chromosome; SCT: stem-cell transplantation; targeted: targeted agent (e.g., tyrosine kinase inhibitor, blinatumomab, inotuzumab); tx: treatment.

prolong RFS compared with chemotherapy among those who did not achieve an early MRD response, but was no better than chemotherapy in patients who did achieve an early MRD response.⁵⁹ Likewise, the PETHEMA ALL-AR03 trial used MRD to guide treatment decisions at the end of consolidation, and found that HSCT could be avoided in patients who reached MRD negativity without adversely affecting their prognosis.⁶⁰ Similarly, a study using the Northern Italy Leukemia Group trial protocol 10/07 implemented risk-stratification to define a cohort of patients with an MRD response who could achieve good outcomes with conventional maintenance instead of HSCT after induction therapy.⁶¹ These studies provide evidence that MRD can play a role in sparing patients from the risks associated with transplantation, without negatively affecting survival outcomes.⁶ New systemic therapies may offer alternatives to HSCT; for example, a phase II study (published in full since the literature review was conducted) found that blinatumomab could induce a complete MRD response in over three-quarters of patients with MRD-positive ALL in first-line treatment,⁶² blinatumomab is now approved for use in patients with MRD-positive ALL in the USA.⁶³ There is a need to establish the role of MRD testing in guiding treatment in each subgroup of patients with ALL and to determine an evidence-based treatment protocol to optimize patients' outcomes.

Ph-positive and Ph-negative disease differ not just in terms of prognosis, but also in treatment regimens and method of MRD assessment. We analyzed RFS separately for Ph-positive and Ph-negative studies, and the prognostic ability of MRD negativity remained the same regardless of Ph status, with no discernible difference among subgroups. Subdividing the total population according to Ph status led to shrinkage or elimination of certain subgroups, but these results again point to the consistency of effect of MRD negativity across clinically relevant populations. It will be important in future research to further dissect the Ph-like subset of patients (who have a similar gene expression profile to Ph-positive ALL but without the targetable *BCR-ABL* translocation), given their poor prognosis and persistence of MRD.⁶⁴

The question of how sensitive MRD assays need to be remains to be resolved. In a study of patients with untreated Ph-negative B-ALL or T-ALL, MRD levels of 10^{-3} or greater were associated with a poor prognosis.⁴⁵ In our study, no real differences in the association between MRD level and outcome were seen, regardless of whether the sensitivity threshold was 10^{-3} , 10^{-4} or 10^{-5} . Therefore, the threshold of 10^{-4} recommended by ESMO seems appropriate.⁶

The studies included in this systematic review and meta-analysis represent a broad range of patient subgroups and treatment regimens. Consequently, the findings should be generalizable across the whole B-ALL population. Nevertheless, these analyses have some limitations. Given the wide range of treatment regimens, follow-up times and methodologies for assessing MRD, the data should be interpreted with caution. Heterogeneity was high (as measured using I^2), but this was expected because it reflects the nature of studies included: they were not randomized and included different populations of patients, methods of analysis, follow-up times and study designs. In addition, treatments administered after MRD assessment, particularly HSCT, would be a major confounding factor when assessing the relationship

between MRD and survival outcomes. We investigated sources of heterogeneity by using predetermined subgroup analyses of factors that might affect MRD and survival, and by using meta-regression. The subgroup analyses support the overall conclusion that MRD negativity is associated with better survival outcomes than MRD positivity. Heterogeneity remained high after accounting for key variables, indicating that there could be additional factors that affect the relative effect of MRD status on outcomes, which we were unable to account for in this analysis. Furthermore, for some subgroups very few studies were available, and data were sparse, meaning that the reliability of some of the subgroup results was suboptimal.

In some cases, time-to-event data were missing, and hazard ratios were calculated using published methodologies to account for this.³⁰ However, the meta-regression for RFS indicated that the Tierney method used to calculate hazard ratios was unlikely to influence the magnitude of the effect of MRD negativity.

It would be of interest to study the impact of MRD on bone marrow relapse. Although RFS is a good proxy for relapse, deaths in remission (e.g., following HSCT) may affect the results. This meta-analysis focused on MRD as a risk factor for systemic relapse and did not examine MRD as a predictor of extramedullary relapse or death from other causes, such as transplant-related mortality; therefore, different rates of death across subgroups from causes other than bone marrow relapse could confound the results. The extent of confounding due to HSCT-related mortality is unclear, however, and only two of the studies included in the meta-analysis comprised solely patients who did not undergo HSCT. Overall, the strong relationship observed in our study, and that by Berry *et al.*,²⁸ highlights the high prognostic value of MRD, despite this confounding factor.

In four studies, it was not possible to separate the B-cell and T-cell populations; however, the majority of patients in these studies had B-ALL (66% to 79%), and there was no difference in the prognostic value of MRD between the B-ALL and mixed studies for either RFS or OS. It should also be noted that our analysis only included two studies in CR2 or later; however, results in this subgroup were consistent with the overall findings.

In conclusion, this systematic review and subsequent meta-analysis have generated support for the use of MRD as a prognostic marker in the management of patients with ALL. Overall, and in all subgroups analyzed, MRD negativity was associated with better survival outcomes than MRD positivity. This finding appeared relatively unaffected by variation in the timing or sensitivity threshold of the MRD assay applied, though other factors – such as the window of opportunity for treatment before relapse – may need to be considered when refining MRD assessment methodology to optimize its value in practice. Detection of MRD offers a promising clinical tool that may help clinicians to harness the potential of emerging targeted therapies for ALL.

Acknowledgments

The authors would like to thank James O'Kelly PhD of Amgen Ltd who provided editorial support, and Kim Allcott PhD of Oxford PharmaGenesis who assisted with the systematic literature review and provided editorial support. This research was funded by Amgen.

References

- Carroll W, Loh M, Biondi A, Willman C. The biology of acute lymphoblastic leukemia. In: Reaman G, Smith F, eds. *Childhood Leukemia: a Practical Handbook*. Berlin and Heidelberg: Springer-Verlag. 2011:29–61.
- Cancer Research UK. Types of acute lymphoblastic leukaemia. 2015. Available from: <http://www.cancerresearchuk.org/about-cancer/acute-lymphoblastic-leukaemia-all/types> (Accessed 24 May 2016).
- Fielding AK. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. *Hematology Am Soc Hematol Educ Program*. 2011;2011(1):231–237.
- Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. *Blood*. 1998;91(11):3995–4019.
- Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. *J Clin Oncol*. 2017;35(9):975–983.
- Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2016;27(Suppl 5):v69–v82.
- Parikh SA, Litzow MR. Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development. *Future Oncol*. 2014;10(14):2201–2212.
- Zhang H, Gu L, Liu T, Chiang KY, Zhou M. Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negative acute lymphoblastic leukemia. *PLoS One*. 2014;9(6):e100960.
- Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. *N Engl J Med*. 2017;376(9):836–847.
- Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. *N Engl J Med*. 2016;375(8):740–753.
- Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. *J Clin Oncol*. 2017;35(16):1795–1802.
- Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. *J Clin Oncol*. 2011;29(5):532–543.
- Hoelzer D. Personalized medicine in adult acute lymphoblastic leukemia. *Haematologica*. 2015;100(7):855–858.
- Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. *Blood*. 2002;99(3):863–871.
- Gökbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). *Hematol Oncol Clin North Am*. 2000;14(6):1307–1325, ix.
- Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. *Blood*. 1995;85(8):2025–2037.
- Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. *Blood*. 2005;106(12):3760–3767.
- Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. *J Clin Oncol*. 2004;22(20):4075–4086.
- Chen X, Xie H, Wood BL, et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. *J Clin Oncol*. 2015;33(11):1258–1264.
- Gökbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. *Blood*. 2012;120(9):1868–1876.
- Scheuring UJ, Pfeifer H, Wassmann B, et al. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment. *Leukemia*. 2003;17(9):1700–1706.
- Bassan R, Intermesoli T, Scattolin A, et al. Minimal residual disease assessment and risk-based therapy in acute lymphoblastic leukemia. *Clin Lymphoma Myeloma Leuk*. 2017;17S:S2–S9.
- Brown PA, Shah B, Advani A, et al. NCCN clinical practice guidelines in oncology with NCCN evidence blocks. Acute lymphoblastic leukemia. Version 1.2018 – December 13, 2018. Available from: https://www.nccn.org/professionals/physician_gls/pdf/all_blocks.pdf (Accessed 31 January 2019).
- Short NJ, Jabbour E, Albitar M, et al. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts. *Am J Hematol*. 2019;94(2):257–265.
- European Medicines Agency. Guideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies. 2018. Available from: https://www.ema.europa.eu/documents/scientific-guideline/draft-guideline-use-minimal-residual-disease-clinical-endpoint-multiple-myeloma-studies_en.pdf (Accessed 25 October 2018).
- Food and Drug Administration. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment – guidance for industry. 2018. Available from: <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM623333.pdf> (Accessed 25 October 2018).
- Bruggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. *Blood Adv*. 2017;1(25):2456–2466.
- Berry DA, Zhou S, Hignley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. *JAMA Oncol*. 2017;3(7):e170580.
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med*. 2009;339:b2700.
- Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials*. 2007;8:16.
- Bachanova V, Marks DI, Zhang MJ, et al. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. *Leukemia*. 2014;28(3):658–665.
- Giebel S, Stella-Holowiecka B, Krawczyk-Kulis M, et al. Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL. *Bone Marrow Transplant*. 2010;45(6):1095–1101.
- Tucunduva L, Ruggeri A, Sanz G, et al. Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European Group for Blood and Marrow Transplantation. *Br J Haematol*. 2014;166(5):749–757.
- Nishiwaki S, Imai K, Mizuta S, et al. Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT. *Bone Marrow Transplant*. 2016;51(1):43–50.
- Wassmann B, Pfeifer H, Stadler M, et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). *Blood*. 2005;106(2):458–463.
- Goekbuget N, Kantarjian H, Brüggemann M, et al. An evaluation of molecular response in a phase 2 open-label, multicenter confirmatory study in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) receiving treatment with the BiTE® antibody construct blinatumomab. *Blood*. 2014;124(21):3704.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177–188.
- Whitehead A. *Meta-Analysis of Controlled Clinical Trials*. Chichester, UK: John Wiley & Sons, Ltd, 2003.
- Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. *Stat Med*. 1998;17(8):841–856.
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557–560.
- Gökbuget N, Dombret H, Bonifacio M, et al. Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL). *Blood*. 2015;126(23):680 (abstract).
- Chiaretti S, Vitale A, Elia L, et al. Multicenter total therapy Gimema LAL 1509 protocol for de novo adult Ph+ acute lymphoblastic leukemia (ALL) patients. Updated results and refined genetic-based prognostic stratification. *Blood*. 2015;126(23):81.
- Jabbour E, Short NJ, Jorgensen JL, et al. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. *Cancer*. 2017;123(2):294–302.
- Ravandi F, Jorgensen JL, O'Brien SM, et al. Minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. *Br J Haematol*.

- 2016;172(3):392–400.
45. Bassan R, Spinelli O, Oldani E, et al. Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia. *Blood Cancer J*. 2014;4:e225.
 46. Beldjord K, Chevret S, Asnafi V, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. *Blood*. 2014;123(24):3739–3749.
 47. Holowiecki J, Krawczyk-Kulis M, Giebel S, et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukemia. The Polish Adult Leukemia Group ALL 4-2002 MRD study. *Br J Haematol*. 2008;142(2):227–237.
 48. Patel B, Rai L, Buck G, et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. *Br J Haematol*. 2010;148(1):80–89.
 49. Bassan R, Masciulli A, Spinelli O, et al. Enhanced survival in adult Philadelphia-negative acute lymphoblastic leukemia (Ph-ALL) with an updated pediatric derived minimal residual disease (MRD)/risk-specific treatment strategy: NILG Study 10. *Haematologica*. 2014;99(Suppl 1):S726.
 50. Weng XQ, Shen Y, Sheng Y, et al. Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia. *Blood Cancer J*. 2013;3:e133.
 51. Yanada M, Sugiura I, Takeuchi J, et al. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. *Br J Haematol*. 2008;143(4):503–510.
 52. Wetzler M, Watson D, Stock W, et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). *Haematologica*. 2014;99(1):111–115.
 53. Yoon JH, Park S, Jeon YW, et al. Comparable long-term outcomes of reduced-intensity and myeloablative conditioning allogeneic hematopoietic cell transplantation by minimal residual disease kinetics during the tyrosine kinase inhibitor-based chemotherapy courses in adults with Philadelphia-chromosome positive acute lymphoblastic leukemia in first remission. *Blood*. 2016;128(22):3979.
 54. Lim S, Joo YD, Sohn SK. Serial monitoring of BCR-ABL by real-time polymerase chain reaction in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib. *Haematologica*. 2016;101(suppl 1):E856.
 55. Short NJ, Jabbour E, Sasaki K, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. *Blood*. 2016;128(4):504–507.
 56. Lussana F, Intermesoli T, Gianni F, et al. Achieving molecular remission before allogeneic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Impact on relapse and long-term outcome. *Blood Marrow Transplant*. 2016;22(11):1983–1987.
 57. Stock W, Luger SM, Advani AD, et al. Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of U.S. Intergroup Trial C10403. *Blood*. 2014;124(21):796.
 58. Brüggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. *Blood*. 2006;107(3):1116–1123.
 59. Dhedin N, Huynh A, Maury S, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. *Blood*. 2015;125(16):2486–2496.
 60. Ribera JM, Oriol A, Morgades M, et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. *J Clin Oncol*. 2014;32(15):1595–1604.
 61. Bassan R, Masciulli A, Intermesoli T, et al. Final results of Northern Italy Leukemia Group (NILG) trial 10/07 combining pediatric-type therapy with minimal residual disease study and risk-oriented hematopoietic cell transplantation in adult acute lymphoblastic leukemia (ALL). *Blood*. 2016;128(22):176.
 62. Gökbuğet N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia. *Blood*. 2018;131(14):1522–1531.
 63. Amgen Inc. BLINCYTO prescribing information. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125557s0131bl.pdf (Accessed 01 May 2018).
 64. Herold T, Gökbuğet N. Philadelphia-like acute lymphoblastic leukemia in adults. *Curr Oncol Rep*. 2017;19(5):31.